Occurrence of breast cancer subtypes in adolescent and young adult women

Breast Cancer Research

Volumn 14, Issue 2, 2012, Pages

  Keegan, Theresa H M ^a,b   DeRouen, Mindy C ^a   Press, David J ^a   Kurian, Allison W ^b   Clarke, Christina A ^a,b  

^a CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GAMMA UROGASTRONE; PROGESTERONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER REGISTRY; CANCER SURVIVAL; CONTROLLED STUDY; ETHNICITY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; RACE; AGE; BREAST TUMOR; METABOLISM; MIDDLE AGED; UNITED STATES;

ADOLESCENT; ADULT; AGE FACTORS; BREAST NEOPLASMS; CALIFORNIA; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; YOUNG ADULT;

EID: 84858817538     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3156     Document Type: Article

References (52)

1. Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer 2008, 8:288-298. 10.1038/nrc2349, 18354417.
2. Gabriel CA, Domchek SM. Breast cancer in young women. Breast Cancer Res 2010, 12:212. 10.1186/bcr2647, 3096966, 21067532.
3. Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg 2009, 208:341-347. 10.1016/j.jamcollsurg.2008.12.001, 3262236, 19317994.
4. Kurian A, Fish K, Shema S, Clarke C. Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res 2010, 12:R99. 10.1186/bcr2780, 3046442, 21092082.
5. Schmidt C. Lack of progress in teen and young adult cancers concerns researchers, prompts study. J Natl Cancer Inst 2006, 98:1760-1763. 10.1093/jnci/djj517, 17179473.
6. Telli ML, Chang ET, Kurian AW, Keegan TH, McClure LA, Lichtensztajn D, Ford JM, Gomez SL. Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat 2011, 127:471-478. 10.1007/s10549-010-1173-8, 20957431.
7. Amirikia KC, Mills P, Bush J, Newman LA. Higher population-based incidence rates of triple-negative breast cancer among young African-American women: jmplications for breast cancer screening recommendations. Cancer 2011, 117:2747-2753. 10.1002/cncr.25862, 21656753.
8. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 2007, 109:1721-1728. 10.1002/cncr.22618, 17387718.
9. Parise CA, Bauer KR, Caggiano V. Variation in breast cancer subtypes with age and race/ethnicity. Crit Rev Oncol Hematol 2010, 76:44-52. 10.1016/j.critrevonc.2009.09.002, 19800812.
10. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. J Am Med Assoc 2006, 295:2492.
11. Bernstein L, Lacey JV. Receptors, associations, and risk factor differences by breast cancer subtypes: positive or negative?. J Natl Cancer Inst 2011, 103:451-453. 10.1093/jnci/djr046, 21346225.
12. California Cancer Reporting System Standards Cancer Reporting in California, System Standards: Abstracting and Coding Procedures for Hospitals 2008, 1. Sacramento: California Cancer Registry, Data Standards and Quality Control Unit, 8, California Cancer Reporting System Standards.
13. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
14. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
15. The 2012 Statistical Abstract: Births, Deaths, Marriages, & Divorces; Table 83. Total Fertility Rate by Race and Hispanic Origin: 1980 to 2008. , http://www.census.gov/compendia/statab/2012/tables/12s0084.pdf
16. Ruggles S, Sobek M, Alexander T, Fitch CA, Goeken R, Hall PK, King M, Ronnander C. Integrated Public Use Microdata Series: version 4.0. 2009, Minneapolis, MN.
17. Surveillance Research Program, National Cancer Institute SEER*Stat software www.seer.cancer.gov/seerstat Version 6. 5.2. Surveillance Research Program, National Cancer Institute.
18. Dawood S, Hu R, Homes MD, Collins LC, Schnitt SJ, Connolly J, Colditz GA, Tamimi RM. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat 2011, 126:185-192. 10.1007/s10549-010-1113-7, 3026074, 20711652.
19. Joslyn SA, Foote ML, Nasseri K, Coughlin SS, Howe HL. Racial and ethnic disparities in breast cancer rates by age: NAACCR Breast Cancer Project. Breast Cancer Res Treat 2005, 92:97-105. 10.1007/s10549-005-2112-y, 15986118.
20. Brinton LA, Sherman ME, Carreon JD, Anderson WF. Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst 2008, 100:1643. 10.1093/jnci/djn344, 2720764, 19001605.
21. Ihemelandu CU, Naab TJ, Mezghebe HM, Makambi KH, Siram SM, Leffall LD, DeWitty RL, Frederick WA. Treatment and survival outcome for molecular breast cancer subtypes in black women. Ann Surg 2008, 247:463-469. 10.1097/SLA.0b013e31815d744a, 18376191.
22. Reynolds P, Hurley S, Goldberg D, Quach T, Rull R, Von Behren J. An excess of breast cancer among young California-born Asian women. Ethn Dis 2011, 21:196-201.
23. Shavers VL, Harlan LC, Stevens JL. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer 2003, 97:134-147. 10.1002/cncr.11051, 12491515.
24. Anderson WF, Jatoi I, Sherman ME. Qualitative age interactions in breast cancer studies: mind the gap. J Clin Oncol 2009, 27:5308. 10.1200/JCO.2009.22.9450, 2773215, 19826117.
25. Heron M, Sutton PD, Xu J, Ventura SJ, Strobino DM, Guyer B. Annual summary of vital statistics: 2007. Pediatrics 2010, 125:4-15. 10.1542/peds.2009-2416, 20026491.
26. Krieger N, Chen JT, Waterman PD. Temporal trends in the black/white breast cancer case ratio for estrogen receptor status: disparities are historically contingent, not innate. Cancer Causes Control 2011, 22:511-514. 10.1007/s10552-010-9710-7, 3042518, 21188492.
27. Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Stefanick ML, Wactawski-Wende J, Kuller LH, Adams-Campbell LL, Lane D, Vitolins M, Kabat GC, Rohan TE, Li CI. Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev 2011, 20:454-463. 10.1158/1055-9965.EPI-10-0974, 3064558, 21364029.
28. Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J, Kuller LH, Adams-Campbell LL, Lane D, Stefanick ML, Vitolins M, Kabat GC, Rohan TE, Li CI. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 2011, 103:470-477. 10.1093/jnci/djr030, 3057984, 21346227.
29. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer 2008, 113:1521-1526. 10.1002/cncr.23786, 2587413, 18726992.
30. Kurian AW. BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. Curr Opin Obstet Gynecol 2010, 22:72-78. 10.1097/GCO.0b013e328332dca3, 19841585.
31. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, Fasching PA, Hein R, Spurdle AB, Blows F, Driver K, Flesch-Janys D, Heinz J, Sinn P, Vrieling A, Heikkinen T, Aittomaki K, Heikkila P, Blomquist C, Lissowska J, Peplonska B, Chanock S, Figueroa J, Brinton L, Hall P, Czene K, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium Studies. J Natl Cancer Inst 2011, 103:250-263. 10.1093/jnci/djq526, 3107570, 21191117.
32. Travis LB, Hill D, Dores GM, Gospodarowicz M, Van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Pukkala E, Lynch CF. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005, 97:1428. 10.1093/jnci/dji290, 16204692.
33. Althuis MD, Brogan DD, Coates RJ, Daling JR, Gammon MD, Malone KE, Schoenberg JB, Brinton LA. Breast cancers among very young premenopausal women (United States). Cancer Causes Control 2003, 14:151-160. 10.1023/A:1023006000760, 12749720.
34. Michels KB, Terry KL, Willett WC. Longitudinal study on the role of body size in premenopausal breast cancer. Arch Intern Med 2006, 166:2395-2402. 10.1001/archinte.166.21.2395, 17130395.
35. Ahn MK, Juon HS, Gittelsohn J. Association of race/ethnicity, socioeconomic status, acculturation, and environmental factors with risk of overweight among adolescents in California, 2003. Prev Chronic Dis 2008, 5:A75. 2483546, 18558025.
36. Babey SH, Hastert TA, Wolstein J, Diamant AL. Income disparities in obesity trends among California adolescents. Am J Public Health 2010, 100:2149-2155. 10.2105/AJPH.2010.192641, 20864702.
37. Gaudet MM, Press MF, Haile RW, Lynch CF, Glaser SL, Schildkraut J, Gammon MD, Douglas Thompson W, Bernstein JL. Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat 2011, 130:587-597. 10.1007/s10549-011-1616-x, 21667121.
38. Malone KE, Daling JR, Neal C, Suter NM, O'Brien C, Cushing-Haugen K, Jonasdottir TJ, Thompson JD, Ostrander EA. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 2000, 88:1393-1402. 10.1002/(SICI)1097-0142(20000315)88:6<1393::AID-CNCR17>3.0.CO;2-P, 10717622.
39. Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, Han JH, Lowstuter K, Longmate J, Sommer SS, Weitzel JN. Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009, 27:1250-1256. 10.1200/JCO.2008.16.6959, 19204208.
40. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006, 25:5846-5853. 10.1038/sj.onc.1209876, 16998499.
41. Haffty B, Choi D, Goyal S, Silber A, Ranieri K, Matloff E, Lee M, Nissenblatt M, Toppmeyer D, Moran M. Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups. Ann Oncol 2009, 20:1653. 10.1093/annonc/mdp051, 19491284.
42. Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, Litton JK, Olopade OI, Hortobagyi GN, Strong LC, Arun BK. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 2012, 118:908-913. 10.1002/cncr.26377, 21761402.
43. Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast cancer in young women: poor survival despite intensive treatment. PLoS One 2009, 4:e7695. 10.1371/journal.pone.0007695, 2770847, 19907646.
44. Agnese DM, Yusuf F, Wilson JL, Shapiro CL, Lehman A, Burak WE. Trends in breast cancer presentation and care according to age in a single institution. Am J Surg 2004, 188:437-439. 10.1016/j.amjsurg.2004.06.029, 15474444.
45. Hede K. Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing. J Natl Cancer Inst 2008, 100:836-837. 844, 10.1093/jnci/djn200, 18544732.
46. Ma H, Luo J, Press MF, Wang Y, Bernstein L, Ursin G. Is there a difference in the association between percent mammographic density and subtypes of breast cancer? Luminal A and triple-negative breast cancer. Cancer Epidemiol Biomarkers Prev 2009, 18:479-485. 10.1158/1055-9965.EPI-08-0805, 19190139.
47. Press MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, Zhou JY, Wardeh R, Li YT, Guzman R, Ma Y, Sullivan-Halley J, Santiago A, Park JM, Riva A, Slamon DJ. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005, 11:6598-6607. 10.1158/1078-0432.CCR-05-0636, 16166438.
48. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795. 10.1200/JCO.2009.25.6529, 2881855, 20404251.
49. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007, 131:18-43.
50. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault R, Topham NS, Ward JH, Winer EP, Wolff AC. Breast cancer: clinical practice guidelines in oncology. J Natl Comp Cancer Netw 2009, 7:122-192.
51. Clegg LX, Reichman ME, Hankey BF, Miller BA, Lin YD, Johnson NJ, Schwartz SM, Bernstein L, Chen VW, Goodman MT, Gomez SL, Graff JJ, Lynch CF, Lin CC, Edwards BK. Quality of race, Hispanic ethnicity, and immigrant status in population-based cancer registry data: implications for health disparity studies. Cancer Causes Control 2007, 18:177-187. 10.1007/s10552-006-0089-4, 17219013.
52. Gomez SL, Glaser SL. Misclassification of race/ethnicity in a population-based cancer registry (United States). Cancer Causes Control 2006, 17:771-781. 10.1007/s10552-006-0013-y, 16783605.